The Sputnik V vaccine against Covid-19, developed by Russia, would be more effective than that produced by Pfizer and BioNTech, with 92% success.
-1605102492.jpg "With 92% efficiency, Russia is also getting closer to a viable vaccine")
- The Sputnik V vaccine works 92%, better than that of Pfizer and BioNTech.
- It would be made using two transformed adenoviruses, into which part of the genetic material of Covid-19 has been integrated.
- Sputnik V is not yet in production but 20 countries have already ordered a billion doses.
The race for the vaccine has been racing in recent days. After the announcement at the beginning of the week of the vaccine developed by the American Pfizer, in partnership with the German BioNTech, it is now Russia’s turn to show the muscles. The Kremlin has announced the success of the Sputnik V vaccine, with an effectiveness rate against Covid-19 of 92%, two percent more than its competitor across the Atlantic.
Better results than Pfizer and BioNTech
The Sputnik V vaccine is developed by the Gamaleya Institute. For its trial, Russia enlisted 16,000 participants, some of whom received a placebo instead of the vaccine. Afterwards, only 20 people contracted Covid-19. According to the Russians, the risk of contracting the coronavirus was 92% lower in people vaccinated with Sputnik V than in those who received the placebo.
These results should be put into perspective with those unveiled at the start of the week by the companies Pfizer and BioNTech, which had a success rate of 90%. Where the two companies based their vaccine on a messenger RNA capable of transmitting instructions to our body, the Russians use two injections of transformed adenoviruses, to which they have attached part of the genetic material responsible for Covid-19.
Turkey as a possible Russian ally
The trials of this new vaccine will continue in the next six months, and the data of the study relating to this project could be published soon according to Moscow. If a vaccine release date is not yet on the agenda, the Turkish government has already indicated that it is interested in producing this remedy within its pharmaceutical companies.
According to Kirill Dmitriev, director of the Russian Direct Investment Fund, the body responsible for developing and marketing this product on a global scale, twenty countries have already placed an order with Russia to obtain this new vaccine, for a total of one billion doses.
.
-1605102492.jpg&description=With+92%25+efficiency%2C+Russia+is+also+getting+closer+to+a+viable+vaccine){kind=link}